As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality.
The first safety trials in humans started as early as March, due to various expedited clinical development processes in place around the globe that promised to bring a vaccine to fruition as quickly as 12 to 18 months from the outbreak of the pandemic—an unprecedented time frame that was quick to spark a reaction from critics.
Download the FULL Pricentric Insights ここ.
NAVLIN Price & Access Data is a powerful competitor intelligence tool that provides near real-time updates to drug price (list / net), reimbursement, tender and cost of treatment information at the indication level. Our…